Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Keros Therapeutics, Inc. on June 6, 2023. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Lexington, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Two nominees were elected to serve until the 2026 Annual Meeting.
- Carl L. Gordon: 11,486,998 votes For; 13,409,802 votes Withheld; 1,896,225 Broker Non-Votes.
- Tomer Kariv: 19,234,712 votes For; 5,662,088 votes Withheld; 1,896,225 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders approved the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes For: 26,790,800
- Votes Against: 2,224
- Votes Abstain: 1
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Carl L. Gordon received more withheld votes than votes for, though he was still elected as a director.
- Deloitte & Touche LLP was ratified as the independent auditor for the 2023 fiscal year.
- The company is classified as an emerging growth company.
- Broker non-votes occurred for the director election but not for the auditor ratification.